Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

Background The tumor antigen NY-ESO-1 has been shown to be an effective target for transgenic adoptive cell therapy (ACT) for the treatment of sarcoma and melanoma. However, despite frequent early clinical responses, many patients ultimately develop progressive disease. Understanding the mechanisms...

Full description

Bibliographic Details
Main Authors: Arun Singh, Begoña Comin-Anduix, Antoni Ribas, Beata Berent-Maoz, Theodore Scott Nowicki, Luke Frankiw, Cole Peters, Mignonette Macabali, Kiana Shammaie, Crystal Quiros, Paula Kaplan-Lefko, Ignacio Baselga Carretero
Format: Article
Language:English
Published: BMJ Publishing Group 2023-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/5/e006930.full

Internet

https://jitc.bmj.com/content/11/5/e006930.full

Similar Items